SummaryPrurigo nodularis (PN) is a chronic, debilitating neuro-immunological skin disease characterized by intense pruritus and hyperkeratotic nodules. Nemolizumab, a novel IL-31 receptor alpha antagonist targeting the neural itch pathway, was investigated in PN. Two randomized phase 3 studies, the Olympia 1 and Olympia 2 trials, provided favorable efficacy and safety data for nemolizumab versus placebo in moderate-to-severe PN. After 16 weeks, a ≥ 4-point reduction in PP-NRS was achieved in 58.4% (Olympia 1) and 56.3% (Olympia 2) of nemolizumab patients compared to 16.7% and 20.9% in placebo groups, respectively (p < 0.001). Safety data showed no drug-related serious adverse events or organ toxicity. These trials were the first to clinically demonstrate IL-31 inhibition in PN. Nemolizumab represents a paradigm shift in PN therapy, acting as a potent 'neuro-modulator' with rapid itch relief, often observed by Week 4. Future management may rely on disease endotypes to select between neural (IL-31) and immune (IL-4/13) blockade.
Lernia et al. (Thu,) studied this question.